Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The role of Tet2-mutant clonal hematopoiesis in solid tumor immunology

Shelley Herbrich, Mehdi Chaib, Swetha Anandhan et al. Nov 03, 2025 pp. 4952-4952 10.1182/blood-2025-4952

Abstract Background: Clonal hematopoiesis (CH) is an age-related condition wherein somatic mutations in hematopoietic stem and progenitor ce...

Elevated p16INK4a expression in sickle cell disease correlates with diminished social functioning and reflects accelerated aging

Samuel Wilson, Ada Chang, Natalia Mitin et al. Nov 03, 2025 pp. 530-530 10.1182/blood-2025-530

Abstract Introduction People living with sickle cell disease (SCD) experience complications indicative of an accelerated...

Pre-clinical evaluation of surovatamig (AZD0486) in comparison to CD20xCD3 bispecific antibodies

Wen Lin, Abigail Lara, Nazli Jafarzadeh et al. Nov 03, 2025 pp. 3312-3312 10.1182/blood-2025-3312

Abstract Background Surovatamig is a novel, fully human IgG4 bispecific T-cell engager (TCE) targeting CD19 and CD3. Engineered with low CD3...

Efficacy and safety of pozelimab plus cemdisiran versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria who received prior C5 therapy

Jun Ho Jang, Christopher Patriquin, Deepak Taneja et al. Nov 03, 2025 pp. 1420-1420 10.1182/blood-2025-1420

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare life-threatening disorder characterized by hemolysis. The cu...

Machine learning-guided optimization of anti-CD70 natural ligand-based CAR-lymphocytes for Acute Myeloid Leukemia

Ruyan Rahnama, Amrik Kang, Radhika Dalal et al. Nov 03, 2025 pp. 5914-5914 10.1182/blood-2025-5914

Abstract Introduction: Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with an urgent need for novel therapies. CD...

Intelligent bispecific BCMA-CD24 CAR-T cells for precision navigation and elimination of multiple myeloma

Shijing Wang, Bin Sun, Ali Ishaq et al. Nov 03, 2025 pp. 800-800 10.1182/blood-2025-800

Abstract Introduction: The high relapse rate following BCMA CAR-T therapy remains a challenge in the treatment of multiple myeloma (MM). We...

MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis

Ayalew Tefferi, Fnu Aperna, Mahesh Kumar et al. Nov 03, 2025 pp. 2017-2017 10.1182/blood-2025-2017

Abstract Background: The International Consensus Classification (ICC) for systemic mastocytosis (SM) recognizes mast cell leukemia (MCL) and...

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Toby Eyre, Matthew S Davids, Jeff Sharman et al. Nov 03, 2025 pp. 5670-5670 10.1182/blood-2025-5670

Abstract Introduction: Patients with CLL/SLL commonly receive a covalent Bruton tyrosine kinase inhibitor (cBTKi) as 1L therapy. However, mo...

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Kateryna Filonenko, Marco Picardi, Michal Kurlapski et al. Nov 03, 2025 pp. 8243-8243 10.1182/blood-2025-8243

Abstract Patients (pts) with early-stage favorable Hodgkin Lymphoma (efHL) have a heterogeneous prognosis: most (70%) are cured with chemoth...

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Amer Zeidan, Anthony Selwyn Stein, Johanna Rimpiläinen et al. Nov 03, 2025 pp. 236-236 10.1182/blood-2025-236

Abstract Introduction Bexmarilimab is a novel macrophage checkpoint inhibitor targeting Clever-1, a scavenger receptor e...

Prognostic impact of the simplified hlama score and treatment-related complications in primary gastric diffuse large b-cell lymphoma: A retrospective study from a latin American center

Luis Felipe Rubalcava, Amaya Llorente-Chávez, Irma Pellon Tellez et al. Nov 03, 2025 pp. 7196-7196 10.1182/blood-2025-7196

Abstract Introduction Primary gastric lymphoma (PGL) is a common site of extranodal diffuse large B cell lymphoma (DLBCL...

New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein

Yaonan Hong, Shiyue Wu, Shun He et al. Nov 03, 2025 pp. 1695-1695 10.1182/blood-2025-1695

Abstract Acute myeloid leukemia (AML) is a malignant blood disease with a poor prognosis. Over the past decades, intensive chemotherapy and...

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu et al. Nov 03, 2025 pp. 6880-6880 10.1182/blood-2025-6880

Abstract Background Combining IKZF1plus genotyping and minimal residual disease status at three months of treatment helps refining risk stra...

BTK inhibition drives mobilization and compartmental shifts of CLL subclones

Christine Gruessner, Victoria Rogness, Bharath Dileep Kumar et al. Nov 03, 2025 pp. 7406-7406 10.1182/blood-2025-7406

Abstract BACKGROUND Chronic lymphocytic leukemia (CLL) shows compartmentalization, whereby genetically or functionally d...

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease

Sarah Nikiforow, Kris Mahadeo, Sridhar Chaganti et al. Nov 03, 2025 pp. 1934-1934 10.1182/blood-2025-1934

Abstract Background: Tabelecleucel is an off-the-shelf, allogenic Epstein-Barr virus (EBV)-specific cytotoxic T cell therapy for relapsed or...

Unusual laboratory manifestations of fibrinogen γ chain p.Ala108Gly genetic variant: A case report

Joseph Mah, Christine Baird, Keith Neeves et al. Nov 03, 2025 pp. 3080-3080 10.1182/blood-2025-3080

Abstract Introduction: Fibrinogen is a dimeric glycoprotein with monomers composed of Aα, Bβ, and γ subunits, which contributes necessary me...

Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials

Abdulrahman Al-Mashdali, Muhammad Ashar Ali, Wajeeha Aiman et al. Nov 03, 2025 pp. 7414-7414 10.1182/blood-2025-7414

Abstract Background: Fixed-duration treatment regimens have emerged as a paradigm shift in first-line chronic lymphocytic leukemia (CLL) man...

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Paola Guglielmelli, Francesca Crupi, Mirko Lomi et al. Nov 03, 2025 pp. 3751-3751 10.1182/blood-2025-3751

Abstract Background. MPN-BP after chronic phase MPN is characterized by dismal outcome, with OS <6 mo. Owing to disappointing results...

Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom

Oliver Tomkins, Hannah Giles, Guy Pratt et al. Nov 03, 2025 pp. 4045-4045 10.1182/blood-2025-4045

Abstract Background Elranatamab is a humanised B-cell maturation antigen (BCMA)-CD3 bispecific antibody. It is available in England and Wales...

Efficacy of novel agents in the treatment of acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis

Hafiz Muhammad Hannan Javed, Moazzam Shahzad, Utsav Joshi et al. Nov 03, 2025 pp. 6934-6934 10.1182/blood-2025-6934

Abstract Introduction: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are two of the most common hematological disorders in...

Modifiable lifestyle factors in patients with myeloproliferative neoplasms in the California teachers study

Elias Gennaoui, Jeffrey Li, Ashley Larsen et al. Nov 03, 2025 pp. 7340-7340 10.1182/blood-2025-7340

Abstract Introduction: Myeloproliferative Neoplasms (MPNs) are a rare set of hematologic malignancies associated with thrombotic complicatio...

Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

Catelyn Cashion, Jian Li, Sergio Farina et al. Nov 03, 2025 pp. 1936-1936 10.1182/blood-2025-1936

Abstract Background: Secondary central nervous system large B-cell lymphoma (sCNSL) carriers a poor prognosis and is often refractory to sta...

The USP22-NAP1L1 deubiquitination axis in the pathogenesis of myelodysplastic syndromes

Lijuan Li, Jiayi Xie, Nan Song et al. Nov 03, 2025 pp. 2059-2059 10.1182/blood-2025-2059

Abstract Background:Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic system diseases with significant heterogeneity. Its pa...

Acute splenic sequestration in children with sickle cell diseases: A single-center experience from Saudi Arabia with proposed management guideline

Abdulaziz Bokhari, Muhammad Alam, Saad Hashmi et al. Nov 03, 2025 pp. 6509-6509 10.1182/blood-2025-6509

Abstract Background Sickle cell disease (SCD) is a common inherited hemoglobin disorder with significant clinical impact worldwide. In Saudi...

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

Basem William, Madiha Iqbal, Natalie Galanina et al. Nov 03, 2025 pp. 4353-4353 10.1182/blood-2025-4353

Abstract Introduction: Among Non-Hodgkin lymphomas (NHL), DLBCL is the most prevalent subtype (~30% of diagnoses). First-line (1L) chemoimmu...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page